AB SCIEX and LECO Announces Co-marketing Agreement
News Mar 20, 2013
LECO Corporation and AB SCIEX have announced a co-marketing agreement to cooperatively offer bundled liquid chromatography (LC) and gas chromatography (GC) mass spectrometry-based solutions to metabolomics researchers who require both types of separation capabilities.
Metabolomics researchers often require the use of both GC/MS and LC/MS technologies to provide comprehensive coverage of the analytes in their biological systems as part of the Systems Biology approach.
The new AB SCIEX/LECO bundled solutions will provide these researchers with high speed, accurate mass capabilities with LC and GC, along with robust nominal mass GC/MS and triple quadrupole mass spectrometry.
Researchers will have at their disposal pairings of time-tested nominal mass systems as well as industry-leading high performance GC-TOF and LC-QTOF MS systems.
The application support and service teams of both companies will work together to ensure that users get the support they need to run their comprehensive experiments.
“As the industry leader in LC/MS, we interact with metabolomics researchers all over the world, and we understand that there are times when metabolomics researchers want to use both GC/MS and LC/MS,” said Aaron Hudson, Senior Director, Academic and Omics Business.
Hudson continued, “Representing a virtual one-stop shop for metabolomics mass spectrometry, the joint bundles from AB SCIEX and LECO provide users with greater flexibility in chromatography while obtaining the rich information that MS/MS delivers.”
“Bringing together leaders in GC/MS and LC/MS and facilitating the availability of our systems as complementary technologies helps ensure that metabolomics researchers can approach their work to obtain the very best data and information available,” said Jeffrey Patrick, Director of Marketed Technologies for LECO.
Patrick continued, “Our leadership in GC/MS technologies is a perfect complement to the offerings of AB SCIEX and puts the combined power of our product portfolios, expertise, services, and support to work for these researchers.”
The joint bundles from AB SCIEX and LECO will be available in North America and Europe.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE